Updated on 2024/10/02

Information

 

写真a

 
YAMAGUCHI KYOKO
 
Organization
Faculty of Medical Sciences Department of Medical Education Assistant Professor
School of Medicine Department of Medicine（Concurrent）
Title
Assistant Professor
Profile
教育：医学部学生の臨床実習、大学院生の講義、研究の指導 研究：腫瘍内科学、腫瘍免疫学、がん遺伝子解析 社会活動：九州大学病院において内科専攻医の臨床教育の指導・管理
External link

Degree

  • PhD

Research Interests・Research Keywords

  • Research theme：Carcinogenesis of gastric cancer, Cancer genomics, Onco-immunology

    Keyword：gastric cancer, cancer genomics, onco-immunology

    Research period： 2021.4

Awards

  • Encouragement Award of Japanese Society of Medical Oncology

    2024.2   Efficacy of Pembrolizumab in metastatic colorectal cancer with TMB-High/non-MSI-high

    　More details

  • 奨励賞

    2024.2   日本臨床腫瘍学会   Efficacy of Pembrolizumab in metastatic Colorectal Cancer with TMB-High/non-MSI-High

Papers

  • Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer Reviewed

    Kyoko Yamaguchi, Mamoru Ito, Taichi Isobe, Sakuya Koreishi, Ryosuke Taguchi, Koki Uehara, Shohei Ueno, Takashi Imajima, Takafumi Kitazono, Kenji Tsuchihashi, Hirofumi Ohmura, Tomoyasu Yoshihiro, Kenro Tanoue, Satoshi Nishiyori, Eiji Iwama, Takahiro Maeda, Koichi Akashi, Eishi Baba

    JCO Precision Oncology   8 ( 8 )   e2300681   2024.3   （ eISSN:2473-4284 ）

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：American Society of Clinical Oncology (ASCO)  

    PURPOSE

    The impact of genomic alterations on response and resistance to trastuzumab deruxtecan (T-DXd) has not been elucidated. Thus, we sought to identify factors predicting sensitivity to T-DXd in gastric or gastroesophageal junction (G/GEJ) cancer.

    METHODS

    We conducted a retrospective study using real-world clinical data and next-generation sequencing–based comprehensive genomic profiling (CGP) data from patients with advanced G/GEJ cancers, collected by the nationwide database in Japan. We analyzed the associations between genomic alterations and the patients' survivals after T-DXd treatment.

    RESULTS

    In 114 patients with human epidermal growth factor receptor-2 (HER2)–positive G/GEJ cancer treated with T-DXd, the most frequently altered genes were TP53 (82%), ERBB2 (80%), and CCNE1 (36%). Multivariate Cox regression analysis revealed CCNE1 amplification to be a significant predictor of shorter progression-free survival (PFS) after T-DXd treatment among 91 patients whose CGP samples were obtained before T-DXd (median PFS, 131 days v 189 days; hazard ratio [HR], 1.90 [95% CI, 1.02 to 3.53]; P = .044). Analyses of 1,450 G/GEJ cancers revealed significant CCNE1/ ERBB2 coamplification (41% relative to 11% CCNE1 amplification in ERBB2-nonamplified tumors; P < .0001). ERBB2-activating mutations were also detected in 3.7% of G/GEJ cancers and in 8.8% of HER2-positive G/GEJ cancers treated with T-DXd. Patients with ERBB2-mutated tumors showed shorter PFS than those without ERBB2 mutations after T-DXd treatment (mPFS, 105 v 180 days; P = .046).

    CONCLUSION

    CCNE1 amplification may confer primary resistance to T-DXd in HER2-positive G/GEJ cancer, suggesting that the cell cycle could be a potential therapeutic target in CCNE1/ERBB2 coamplified tumors. ERBB2-activating mutation may also attenuate T-DXd efficacy in HER2-positive G/GEJ cancer.

    DOI： 10.1200/PO.23.00681

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition Reviewed

    Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi

    Cancer Science   115 ( 3 )   1014 - 1021   2024.1   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Abstract

    Molecular testing to determine optimal therapies is essential for managing patients with colorectal cancer (CRC). In October 2022, the Japanese Society of Medical Oncology published the 5th edition of the Molecular Testing Guideline for Colorectal Cancer Treatment. In this guideline, in patients with unresectable CRC, RAS/BRAF V600E mutational and mismatch repair tests are strongly recommended prior to first‐line chemotherapy to select optimal first‐ and second‐line therapies. In addition, HER2 testing is strongly recommended because the pertuzumab plus trastuzumab combination is insured after fluoropyrimidine, oxaliplatin, and irinotecan in Japan. Circulating tumor DNA (ctDNA)‐based RAS testing is also strongly recommended to assess the indications for the readministration of anti‐EGFR antibodies. Both tissue‐ and ctDNA‐based comprehensive genomic profiling tests are strongly recommended to assess the indications for targeted molecular drugs, although they are currently insured in patients with disease progression after receiving standard chemotherapy (or in whom disease progression is expected in the near future). Mutational and mismatch repair testing is strongly recommended for patients with resectable CRC, and RAS/BRAF V600E mutation testing is recommended to estimate the risk of recurrence. Mutational and mismatch repair and BRAF testing are also strongly recommended for screening for Lynch syndrome. Circulating tumor DNA‐based minimal residual disease (MRD) testing is strongly recommended for estimating the risk of recurrence based on clinical evidence, although MRD testing was not approved in Japan at the time of the publication of this guideline.

    DOI： 10.1111/cas.16039

    Web of Science

    Scopus

    PubMed

    researchmap

  • Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model Reviewed International journal

    Kyoko Yamaguchi, Tomoyasu Yoshihiro, Hiroshi Ariyama, Mamoru Ito, Michitaka Nakano, Yuichiro Semba, Jumpei Nogami, Kenji Tsuchihashi, Takuji Yamauchi, Shohei Ueno, Taichi Isobe, Koji Shindo, Taiki Moriyama, Kenoki Ohuchida, Masafumi Nakamura, Yoshihiro Nagao, Tetsuo Ikeda, Makoto Hashizume, Hiroyuki Konomi, Takehiro Torisu, Takanari Kitazono, Tomohiro Kanayama, Hiroyuki Tomita, Yoshinao Oda, Hitoshi Kusaba, Takahiro Maeda, Koichi Akashi, Eishi Baba

    Gastric Cancer   2022.6

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10120-022-01307-8.

  • Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report Reviewed International journal

    Kyoko Yamaguchi, Kenji Tsuchihashi, Kunihiro Tsuji, Yosuke Kito, Kenro Tanoue, Hirofumi Ohmura, Mamoru Ito, Taichi Isobe, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    100 ( 19 )   e25773   2021.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/MD.0000000000025773.

  • OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody Reviewed

    Hirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, Mamoru Ito, Akitaka Makiyama, Keita Uchino, Hozumi Shimokawa, Shingo Tamura, Taito Esaki, Kenji Mitsugi, Yoshihiro Shibata, Hisanobu Oda, Kenji Tsuchihashi, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

    British Journal of Cancer   122 ( 10 )   1507 - 1517   2020.5

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41416-020-0810-1

  • Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer Reviewed

    Kyoko Yamaguchi, Mamoru Ito, Hirofumi Ohmura, Fumiyasu Hanamura, Michitaka Nakano, Kenji Tsuchihashi, Shuntaro Nagai, Hiroshi Ariyama, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Masafumi Nakamura, Koichi Akashi, Eishi Baba

    OncoImmunology   9 ( 1 )   1724763 - 1724763   2020.1

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/2162402x.2020.1724763

  • Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody Reviewed

    Kyoko Yamaguchi, Koji Mishima, Hirofumi Ohmura, Fumiyasu Hanamura, Mamoru Ito, Michitaka Nakano, Kenji Tsuchihashi, Shun-Ichiro Ota, Naoko Wada, Hiroshi Uchi, Hiroshi Ariyama, Hitoshi Kusaba, Hiroaki Niiro, Koichi Akashi, Eishi Baba

    Cancer Science   109 ( 10 )   3032 - 3042   2018.10

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.13758

  • Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions. International journal

    Koki Uehara, Kenro Tanoue, Kyoko Yamaguchi, Hirofumi Ohmura, Mamoru Ito, Yuzo Matsushita, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Taichi Isobe, Yoshihiro Shibata, Hiroshi Ariyama, Risa Tanaka, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Cancer immunology, immunotherapy : CII   72 ( 11 )   3543 - 3558   2023.8   （ ISSN:0340-7004 eISSN:1432-0851 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The present study prospectively examined 22 patients scheduled to receive ICB for unresectable or metastatic RCC between March 2018 and August 2021. Eleven patients received combined therapy with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab), and the other 11 patients received nivolumab monotherapy. Comprehensive phenotypes of circulating immune cells obtained prior to and after ICB therapy were analyzed by flow cytometry. Although the proportion of naïve B cells among total B cells was significantly decreased, that of switched memory B cells was significantly increased after combined therapy. In responders, the proportion of B cells among peripheral blood mononuclear cells was significantly higher prior to ICB therapy, and the proportion of switched memory B cells among total B cells tended to increase after ICB therapy. Of note, the proportion of plasmablasts among total B cells was significantly increased after ICB therapy in patients who developed severe immune-related adverse events (irAEs), and the proportion of B cells among peripheral blood decreased significantly. Furthermore, in four of five patients who developed immune-related hypophysitis following combined therapy, anti-pituitary antibody was detected in the serum. These results suggested that immune-related hypophysitis was closely related to the increase in circulating plasmablasts. Collectively, this study suggests that combined ICB promotes the differentiation of B cell populations, which is associated with efficient tumor suppression and development of irAEs.

    DOI： 10.1007/s00262-023-03505-4

    Web of Science

    Scopus

    PubMed

    researchmap

  • RHAMM marks proliferative subpopulation of human colorectal cancer stem cells.

    Michitaka Nakano, Taguchi R, Kikushige Y, Taichi Isobe, Kohta Miyawaki, Mizuno S, Tsuruta N, Hanamura F, Yamaguchi K, Yamauchi T, Hiroshi Ariyama, Kusaba H, Nakamura M, Maeda T, Kuo CJ, Eishi Baba, Akashi K

    Cancer science   114 ( 7 )   2895 - 2906   2023.3   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    The cancer stem cell (CSC) theory features typically rare self-renewing subpopulation that reconstitute the heterogeneous tumor. Identification of molecules which characterize the feature of CSCs is a key imperative for further understanding of tumor heterogeneity and for the development of novel therapeutic strategies. However, the use of conventional markers of CSCs is still insufficient for the isolation of bona fide CSCs. We investigated organoids which are miniature forms of tumor tissues with reconstructing cellular diversity to identify specific marker to characterize CSCs in heterogeneous tumors. Here, we report that receptor for hyaluronan-mediated motility (RHAMM) expresses in a subpopulation of CD44+ conventional human colorectal CSC fraction. Single-cell transcriptomics of organoids highlighted RHAMM positive proliferative cells that revealed distinct characteristics among the various cell types. Prospectively isolated RHAMM+ CD44+ cells from the human colorectal cancer tissues showed highly proliferative character with self-renewal ability in comparison with the other cancer cells. Furthermore, inhibition of RHAMM strongly suppressed organoids formation in vitro and inhibited the tumor growth in vivo. Our findings suggest that RHAMM is a potential therapeutic target because it is a specific marker of the proliferative subpopulation within the conventional CSC fraction.

    DOI： 10.1111/cas.15795

    Web of Science

    Scopus

    PubMed

    researchmap

  • Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer. International journal

    Tomoyasu Yoshihiro, Hiroshi Ariyama, Kyoko Yamaguchi, Takashi Imajima, Satoru Yamaga, Kenji Tsuchihashi, Taichi Isobe, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Cancer science   113 ( 12 )   4207 - 4218   2022.9   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC, especially those with cancers harboring the BRAF mutation, could benefit from such agents. However, two MTAs, eribulin (Eri) and vinorelbine, have shown limited clinical efficacy. Here, we report that insulin-like growth factor 1 receptor (IGF-1R) signaling is involved in Eri resistance. Using CRC cell lines, we showed that Eri induces activation and subsequent translocation of IGF-1R to the nucleus. When the activation and/or nuclear translocation of IGF-1R was inhibited, Eri induced DNA damage and enhanced G2 /M arrest. In a xenograft model using the Eri-resistant SW480 cell line, the combination of Eri and the IGF-1R inhibitor linsitinib suppressed tumor growth more efficiently than either single agent. Thus, our results indicated that combination dosing with Eri and an IGF-1R inhibitor could overcome Eri resistance and offer a therapeutic opportunity in CRC.

    DOI： 10.1111/cas.15558

    Web of Science

    Scopus

    PubMed

    researchmap

  • Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions Reviewed International journal

    Mamoru Ito, Michitaka Nakano, Hiroshi Ariyama, Kyoko Yamaguchi, Risa Tanaka, Yuichiro Semba, Takeshi Sugio, Kohta Miyawaki, Yoshikane Kikushige, Shinichi Mizuno, Taichi Isobe, Kenro Tanoue, Ryosuke Taguchi, Shohei Ueno, Takahito Kawano, Masaharu Murata, Eishi Baba, Koichi Akashi

    Cancer Letters   532   215597   2022.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Spontaneous Regression of Metachronous Intra-Abdominal Desmoid Tumor in a Patient with Familial Adenomatous Polyposis Reviewed International journal

    Kenji Tsuchihashi, Kyoko Yamaguchi, Ryosuke Taguchi, Kenichi Kohashi, Kayo Ijichi, Yuta Okumura, Michitaka Nakano, Akari Ohno, Tomonobu Hioki, Hozumi Shimokawa, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Case Reports in Oncology   15   71 - 77   2022.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin Reviewed

    Kenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Takashi Imajima, Yudai Shinohara, Mamoru Ito, Satoru Yamaga, Kenro Tanoue, Kohei Arimizu, Hirofumi Ohmura, Fumiyasu Hanamura, Kyoko Yamaguchi, Taichi Isobe, Hiroshi Ariyama, Yasuharu Nakashima, Koichi Akashi, Eishi Baba

    Scientific Reports   10 ( 1 )   2020.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-020-77898-y

  • Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer Reviewed

    Ryosuke Taguchi, Kenji Tsuchihashi, Yuta Okumura, Michitaka Nakano, Tomoyasu Yoshihiro, Hirofumi Ohmura, Nobuhiro Tsuruta, Fumiyasu Hanamura, Kyoko Yamaguchi, Mamoru Ito, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Internal Medicine   59 ( 20 )   2571 - 2575   2020.10

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.2169/internalmedicine.4785-20

  • RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells Reviewed

    Nobuhiro Tsuruta, Kenji Tsuchihashi, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Biochemical and Biophysical Research Communications   530 ( 1 )   235 - 239   2020.9

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbrc.2020.06.153

  • Methylation of drug resistance‐related genes in chemotherapy‐sensitive Epstein–Barr virus‐associated gastric cancer Reviewed

    10 ( 1 )   147 - 157   2020.1

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/2211-5463.12765

  • Epithelial‐mesenchymal transition is activated in CD 44‐positive malignant ascites tumor cells of gastrointestinal cancer Reviewed

    109 ( 11 )   3461 - 3470   2018.11

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.13777

  • The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer Reviewed

    Kyoko Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, Kenji Mitsugi, Keita Uchino, Shingo Tamura, Yoshihiro Shibata, Taito Esaki, Mamoru Ito, Kotoe Takayoshi, Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    Cancer Chemotherapy and Pharmacology   82 ( 4 )   625 - 633   2018.10

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00280-018-3652-2

  • PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer Reviewed

    Michitaka Nakano, Mamoru Ito, Risa Tanaka, Kyoko Yamaguchi, Hiroshi Ariyama, Kenji Mitsugi, Tomoyasu Yoshihiro, Hirofumi Ohmura, Nobuhiro Tsuruta, Fumiyasu Hanamura, Kosuke Sagara, Yuta Okumura, Kenta Nio, Kenji Tsuchihashi, Shuji Arita, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Cancer Science   109 ( 9 )   2986 - 2992   2018.9

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.13723

  • Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation Reviewed

    Kensuke Sasaki, Yasuo Mori, Goichi Yoshimoto, Teppei Sakoda, Koji Kato, Kyoko Inadomi, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi

    Leukemia & Lymphoma   59 ( 8 )   2005 - 2007   2018.8

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428194.2017.1403021

  • A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy Reviewed

    Hozumi Kumagai, Hitoshi Kusaba, Takeharu Yamanaka, Kenta Nio, Kyoko Inadomi, Kotoe Takayoshi, Mamoru Ito, Shingo Tamura, Akitaka Makiyama, Chinatsu Makiyama, Gen Hirano, Yoshihiro Shibata, Tsuyoshi Shirakawa, Kenji Mitsugi, Hiroshi Ariyama, Taito Esaki, Koichi Akashi, Eishi Baba

    Medicine   97 ( 25 )   e11042 - e11042   2018.6

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/md.0000000000011042

  • Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma Reviewed

    Nobuhiro Tsuruta, Kotoe Takayoshi, Shuji Arita, Tomomi Aikawa, Hiroshi Ariyama, Hitoshi Kusaba, Kenoki Ohuchida, Eishi Nagai, Kenichi Kohashi, Minako Hirahashi, Kyoko Inadomi, Mamoru Tanaka, Kosuke Sagara, Yuta Okumura, Kenta Nio, Michitaka Nakano, Masafumi Nakamura, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Oncology Letters   14 ( 2 )   1500 - 1504   2017.8

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.3892/ol.2017.6299

  • Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer Reviewed

    Kotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, Kenji Mitsugi, Chinatsu Makiyama, Akitaka Makiyama, Keita Uchino, Tsuyoshi Shirakawa, Yoshihiro Shibata, Yudai Shinohara, Kyoko Inadomi, Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Taito Esaki, Koichi Akashi, Eishi Baba

    Cancer Chemotherapy and Pharmacology   80 ( 2 )   333 - 342   2017.8

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00280-017-3371-0

  • Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy Reviewed

    Hitoshi Kusaba, Hozumi Kumagai, Kyoko Inadomi, Tomoya Matsunobu, Katsumi Harimaya, Kotoe Takayoshi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    Medicine   95 ( 49 )   e5460 - e5460   2016.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/md.0000000000005460

  • Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus Reviewed

    Kyoko Inadomi, Hozumi Kumagai, Shuji Arita, Nobuhiro Tsuruta, Kotoe Takayoshi, Koji Mishima, Shun-Ichiro Ota, Mamoru Tanaka, Yuta Okumura, Kosuke Sagara, Kenta Nio, Michitaka Nakano, Hiroshi Uchi, Hidetaka Yamamoto, Hiroshi Ariyama, Hitoshi Kusaba, Hiroaki Niiro, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Medicine   95 ( 29 )   e4283 - e4283   2016.7

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/md.0000000000004283

  • Intraluminal superior vena cava metastasis from adenosquamous carcinoma of the duodenum: A case report Reviewed

    KOTOE TAKAYOSHI, HIROSHI ARIYAMA, SHINGO TAMURA, SHUNSUKE YODA, TAKESHI ARITA, TOSHIHIRO YAMAGUCHI, KEIGO OZONO, HIDETAKA YAMAMOTO, KYOKO INADOMI, HOZUMI KUMAGAI, MAMORU TANAKA, YUTA OKUMURA, KOSUKE SAGARA, KENTA NIO, MICHITAKA NAKANO, SHUJI ARITA, HITOSHI KUSABA, KEITA ODASHIRO, YOSHINAO ODA, KOICHI AKASHI, EISHI BABA

    Oncology Letters   11 ( 1 )   605 - 609   2016.1

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.3892/ol.2015.3938

  • Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report Reviewed

    KYOKO INADOMI, HOZUMI KUMAGAI, KOTOE TAKAYOSHI, HIROSHI ARIYAMA, HITOSHI KUSABA, AKIHIRO NISHIE, HIDETAKA YAMAMOTO, KEN TAKASE, MAMORU TANAKA, KOSUKE SAGARA, YUTA OKUMURA, KENTA NIO, MICHITAKA NAKANO, SHUJI ARITA, YOSHINAO ODA, KOICHI AKASHI, EISHI BABA

    Oncology Letters   10 ( 5 )   2981 - 2985   2015.11

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.3892/ol.2015.3708

  • Primary Malignant Melanoma of the Esophagus With Extensive Intraepithelial Extension Reviewed

    Kyoko Inadomi, Takatsugu Ishimoto, Masayuki Watanabe, Masaaki Iwatsuki, Kota Arima, Satoshi Ida, Yohei Nagai, Shiro Iwagami, Yoshifumi Baba, Yasuo Sakamoto, Yuji Miyamoto, Yumi Honda, Ken-ichi Iyama, Hideo Baba

    The Annals of Thoracic Surgery   94 ( 6 )   2105 - 2107   2012.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.athoracsur.2012.04.127

▼display all

Books

  • 大腸がん診療における遺伝子関連検査等のガイダンス

    日本臨床腫瘍学会

    金原出版  2023.3    （ ISBN:9784307204699 ）

    　More details

    Total pages：xvi, 97p   Language：Japanese  

    CiNii Books

    researchmap

Presentations

▼display all

MISC

  • Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition(タイトル和訳中)

    Bando Hideaki, Yamaguchi Kyoko, Mitani Seiichiro, Sawada Kentaro, Mishima Saori, Komine Keigo, Okugawa Yoshinaga, Hosoda Waki, Ebi Hiromichi, Japanese Society of Medical Oncology

    Cancer Science   115 ( 3 )   1014 - 1021   2024.3   （ ISSN:1347-9032 ）

    　More details

    Language：English   Publisher：John Wiley & Sons Australia, Ltd  

  • 【食道・胃・大腸癌の最新情報】進行再発消化管癌に対する最新の集学的治療

    山口 享子, 馬場 英司

    臨牀と研究   100 ( 6 )   721 - 724   2023.6   （ ISSN:0021-4965 ）

    　More details

    Language：Japanese   Publisher：大道学館出版部  

  • MSI-High 固形がん Reviewed

    ＠山口享子,＠馬場英司

    がん最新の薬物療法　2023-2024   2023.3

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 臓器横断的がんゲノム医療の現状と将来展望

    山口享子、伊東守、馬場英司

    腫瘍内科   2022.1

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 【がんゲノム医療の進歩と問題点】臓器横断的がんゲノム医療の現状と将来展望

    山口 享子, 伊東 守, 馬場 英司

    腫瘍内科   29 ( 1 )   11 - 16   2022.1   （ ISSN:1881-6568 ）

    　More details

    Language：Japanese   Publisher：(有)科学評論社  

  • Circulating stem-like PD-1+ CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer

    田ノ上絢郎, 大村洋文, 山口享子, 土橋賢司, 田村真吾, 磯部大地, 有山寛, 江崎泰斗, 赤司浩一, 馬場英司

    日本癌学会学術総会抄録集(Web)   81st   2022

    　More details

▼display all

Professional Memberships

  • 日本内科学会

  • 日本癌学会

  • 日本胃癌学会

  • 日本臨床腫瘍学会

Academic Activities

  • 大腸がん診療における遺伝子関連検査等のガイダンス　第5版　日本臨床腫瘍学会編

    2022.5 - 2023.7

    　More details

    Type：Academic society, research group, etc. 

Research Projects

  • がんゲノム解析に基づいたTMB-High大腸癌の成因解明と免疫チェックポイント阻害薬の効果予測バイオマーカーの創出

    2024.4

  • HER2陽性胃癌のゲノム異常と微小環境に基づく抗HER2抗体薬物複合体の耐性機序の探索

    2023.5

    　 More details

    Authorship：Principal investigator 

  • 消化器癌患者末梢血とTLSにおける腫瘍特異的CD8+T細胞の疲弊ステージの解析

    Grant number：23K07376  2023.4 - 2026.3

    科学研究費助成事業  基盤研究(C)

    馬場 英司, 山口 享子

    　 More details

    Grant type：Scientific research funding

    腫瘍特異的CD8+T細胞は二次リンパ組織（SLO）で抗原提示を受け活性化する過程で疲弊T細胞（Tex）となり、その発現分子と機能により定義される3つの階層的なステージを経て疲弊が進行する。免疫チェックポイント阻害（ICB）は、SLOにおけるTexを再活性化することで抗腫瘍効果をもたらす。一方で、腫瘍組織中の三次リンパ組織様構造（TLS）においてもCD8+T細胞への腫瘍抗原提示は行われているが、そのTexのステージやICBへの反応性は不明である。本研究では腫瘍組織TLSのCD8+T細胞の疲弊状態を解明し、ICB効果との関連と共に、末梢循環中のSLO由来Texとの機能的差異を探索する。

    CiNii Research

  • HER2陽性胃癌のゲノム異常と微小環境に基づく抗HER2抗体薬物複合体の耐性機序の探索

    2023 - 2025

    日本学術振興会  科学研究費助成事業  若手研究

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • HER2陽性胃癌のゲノム異常と微小環境に基づく抗HER2抗体薬物複合体の耐性機序の探索

    Grant number：23K14597  2023 - 2025

    日本学術振興会  科学研究費助成事業  若手研究

    山口 享子

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    HER2陽性胃癌に対して、抗HER2抗体薬物複合体であるトラスツズマブデルクステカンが承認されています。しかし治療当初より治療効果が乏しい方や治療経過とともに治療が効かなくなる方が多数です(薬剤耐性)。本研究では、本薬剤の耐性機序を解明することを目的に、がん細胞の遺伝子異常とその意義を解析します。また、腫瘍内に存在するリンパ節様構造(三次リンパ組織)に着目し、三次リンパ組織の構成細胞を調べることで、腫瘍局所での免疫応答の差異を評価します。本研究では、がん細胞の遺伝子異常および免疫応答に応じた適切な治療法の選択と、抗HER2抗体薬物複合体の耐性打破のための一助となることを目指し研究を行います。

    CiNii Research

  • がんゲノム解析に基づいたTMB-High大腸癌の成因解明と免疫チェックポイント阻害薬の効果予測バイオマーカーの創出

    2023 - 2024

    令和５年度新日本先進医療研究財団助成金

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • TMB-High固形腫瘍に対する抗PD-1/PD-L1抗体薬の有効性に関する探索的研究

    2022 - 2023

    ふくおか公衆衛生推進機構　令和4年度がん研究助成金

    　 More details

    Authorship：Principal investigator  Grant type：Contract research

  • Exploratory study of genomic abnormalities and microenvironment of HER2 gastric cancer that confers resistance to anti-HER2 antibody-drug conjugate

    Grant number：21K20839  2021 - 2022

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Research Activity start-up

    Yamaguchi Kyoko

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    First, to investigate the relationship between specific genomic alterations and treatment efficacy, we concluded a contract with the Center for Cancer Genomics and Advanced Therapeutics of the National Cancer Center and analyzed the results of comprehensive genomic profiling tests conducted in Japan. The results showed that HER2-positive gastric cancer patients with a specific genomic alteration tended to have a poorer response to anti-HER2 drug conjugate than those without the alteration. We are analyzing the mechanism by which this genetic alteration is involved in drug resistance.
    We are also focusing on lymph node-like structures (tertiary lymphoid structure) that form within cancer, and using multiple fluorescent immunostaining and comprehensive genetic analysis techniques, we are evaluating the correlation between the constituent cells of tertiary lymphoid tissues and the therapeutic effect of drugs.

    CiNii Research

  • HER2陽性胃癌において抗HER2抗体薬物複合体に薬剤耐性を付与するがんゲノム異常と免疫逃避機構の探索

    2021

    QRプログラム　わかばチャレンジ

    　 More details

    Grant type：On-campus funds, funds, etc.

▼display all

Specialized clinical area

  • Other

    腫瘍内科学

Clinician qualification

  • Specialist

    Japanese Society of Medical Oncology（JSMO）

  • Certifying physician

    The Japanese Society of Internal Medicine（JSIM）

  • Specialist

    The Japanese Society of Internal Medicine（JSIM）

Year of medical license acquisition

  • 2011